VGS-001
Phase 1- Indications
- Canine oral melanoma
Company intelligence / Profile preview
Vetigenics
Philadelphia, Pennsylvania, United Statesvetigenics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Vetigenics has demonstrated safety of its lead candidate VGS‑001, a fully canine anti‑CTLA4 monoclonal antibody, in dogs. Plans are underway for clinical trials targeting malignant melanoma. The company’s pipeline includes additional immunomodulators at various stages of production and testing to address cancer, infections, and immune-mediated chronic diseases in pets.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Single chain variable fragments (scFvs)Immunomodulators
- Industry
- Veterinary
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Merck Animal Health / Merck & Co., Inc.: Discovery collaboration using CANIBODY™ platform to develop novel therapeutic antibodies for pet health.
Beyond the preview
Go deeper on Vetigenics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vetigenics.